Article Text

Download PDFPDF
Evolution of the definition of myocardial infarction: what are the implications of a new universal definition?

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding: Research Grants>$10 000 from: Sanofi Aventis, Eli Lilly, Merck Sharpe & Dohme, Medicines Company, Neuren Pharmaceuticals, NIH, GlaxoSmithKline, Pfizer, Roche, Fournier Laboratories, Johnson & Johnson, Schering Plough, Janssen-Cilag; Consulting Fees: Medicure<$10 000, Medicines Company<$10 000, Neuren Pharmaceuticals<$10 000, GlaxoSmithKline<$10 000, Bayer<$10 000, Sanofi Aventis<$10 000; Speaker’s Honorarium: Sanofi Aventis<$10 000.

  • Competing interests: None.